Current status and thoughts of PSMA PET/CT imaging application for prostate cancer / 西安交通大学学报(医学版)
Journal of Xi'an Jiaotong University(Medical Sciences)
;
(6): 163-167, 2022.
Article
Dans Chinois
| WPRIM
| ID: wpr-1011584
ABSTRACT
In recent years, PET/CT imaging targeting prostate specific membrane antigen (PSMA) has been increasingly used in the diagnosis and treatment of prostate cancer. PSMA PET/CT has high sensitivity, strong specificity and good diagnostic efficiency for primary and metastatic lesions in prostate cancer. It is suitable for staging, restaging and detection of early biochemical recurrence. It is more accurate and comprehensive than conventional imaging methods for detection of occult lymph node and bone metastasis. Moreover, PSMA PET/CT shows good application prospects in tumor localization, radiotherapy biological target contour, efficacy evaluation, and prognosis prediction of prostate cancer, and may become a clinical indication in the future. False positive and false negative are important problems affecting the judgment of imaging. With the continuous accumulation of clinical experience and constant in-depth clinical research, the reporting accuracy will continue to improve.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
langue:
Chinois
Texte intégral:
Journal of Xi'an Jiaotong University(Medical Sciences)
Année:
2022
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS